Table 12.
Item | MUC2 | IgA | ZO1 | ZO2 | CLDN1 | CLDN5 | OCLN | NFKB1 | TLR2B | TLR4 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Main effect | |||||||||||
OABF1 | No | 1.196 | 2.925 | 1.89 | 1.52 | 1.32 | 1.79 | 1.52 | 1.23 | 1.97 | 2.07 |
Yes | 0.851 | 3.426 | 1.00 | 1.10 | 1.38 | 0.83 | 0.99 | 1.24 | 1.47 | 1.16 | |
Avilamycin2 | No | 1.019 | 3.412 | 1.88 | 1.42 | 1.64 | 1.86 | 1.60 | 1.55 | 2.49 | 2.25 |
Yes | 1.028 | 2.938 | 1.01 | 1.20 | 1.05 | 0.77 | 0.91 | 0.92 | 0.96 | 0.97 | |
Treatments3 | |||||||||||
CON | 1.049 | 3.753 | 2.82a | 2.03a | 2.06a | 2.67a | 2.14 | 1.74 | 3.06 | 3.11 | |
OA | 0.988 | 3.072 | 0.94b | 0.81b | 1.23ab | 1.04b | 1.07 | 1.35 | 1.92 | 1.39 | |
OAAV | 0.714 | 3.780 | 1.07b | 1.40ab | 1.53ab | 0.62b | 0.91 | 1.12 | 1.02 | 0.92 | |
AV | 1.343 | 2.096 | 0.95b | 1.02b | 0.57b | 0.92b | 0.90 | 0.72 | 0.89 | 1.02 | |
Statistics | |||||||||||
SEM4 | 0.148 | 0.770 | 0.344 | 0.341 | 0.334 | 0.331 | 0.295 | 0.262 | 0.565 | 0.490 | |
PO | 0.027 | 0.520 | 0.016 | 0.228 | 0.859 | 0.003 | 0.169 | 0.974 | 0.381 | 0.073 | |
PA | 0.947 | 0.543 | 0.016 | 0.533 | 0.085 | 0.001 | 0.018 | 0.024 | 0.011 | 0.014 | |
PO×A | 0.065 | 0.136 | 0.007 | 0.027 | 0.012 | 0.036 | 0.125 | 0.140 | 0.272 | 0.110 |
MUC2 = mucin 2; IgA = immunoglobulin A; ZO1 = zonula occludens-1; ZO2 = zonula occludens-2; CLDN1 = claudin-1; CLDN5 = claudin-5; CLDN = occludin; NFKB1 = nuclear factor kappa B subunit 1; TLR2B = toll-like receptor 2 family member B; TLR4 = toll-like receptor 4.
a, b Interaction means within the same column differ significantly (P ≤ 0.05).
No: no OABF addition; Yes: addition of 1 g OABF/kg diet.
No: no avilamycin addition; Yes: addition of 2.5 mg of avilamycin/kg diet.
Interaction means from 8 replicate pens per treatment. Treatments include: control – no additions (CON), 1 g OABF/kg diet (OA), avilamycin 2.5 mg active components/kg diet (AV) and combination of OA + AV (OAAV).
Pooled standard error of means.